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J PIntroduction: In children with sickle cell disease (SCD), concomitant asthma is associated with
increased morbidity and mortality when compared with children with SCD without asthma. Despite
the well-established burden of asthma in children with SCD, no paradigm of care exists for the co-
management of these two diseases.
Methods: To address this gap, an integrated SCD and asthma clinic was created in a community
health center that included (1) a dual respiratory therapist/asthma case manager; (2) an SCD nurse
practitioner with asthma educator certiﬁcation; (3) an onsite pulmonary function test laboratory; (4)
a pediatric hematologist with expertise in managing SCD and asthma; and (5) application of the
National Asthma Education and Prevention Program guidelines. A before (2010–2012) and after
(2013–2014) study design was used to assess for improved quality of care with implementation of an
integrative care model among 61 children with SCD and asthma followed from 2010 to 2014.
Results: Asthma action plan utilization after initial diagnosis increased with the integrative care
model (n¼16, 56% before, 100% after, p¼0.003), as did the use of spirometry in children aged ≥5
years (n¼41, 65% before, 95% after, po0.001) and correction of lower airway obstruction (n¼10,
30% before, 80% after, p¼0.03).
Conclusions: Although the use of an integrative care model for SCD and asthma improved
evidence-based asthma care, longer follow-up and evaluation will be needed to determine the impact
on SCD-related morbidity.
(Am J Prev Med 2016;51(1S1):S62–S68) & 2016 American Journal of Preventive Medicine. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionSickle cell disease (SCD) is an inherited red bloodcell disorder characterized by hemolysis and vas-cular occlusion, affecting an estimated 100,000
individuals in the U.S.1 Vaso-occlusive pain is the leading
cause of emergency department (ED) and hospital use
among children with SCD, followed by acute chest
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open access article under the CC BY-NCoccurring in as many as 25% of unselected children with
SCD,2 which increases the rate of vaso-occlusive pain and
ACS.3 Multiple prospective studies have demonstrated
that a diagnosis of asthma or history of recurrent
wheezing in children with SCD is associated with
premature mortality when compared with individuals
with SCD without asthma or recurrent wheezing.4–6
Very few practice models exist for the management of
comorbid conditions. Furthermore, children with public
health insurance face barriers to specialty care access. An
audit study examining scheduling behaviors among specialty
clinics demonstrated disparate access to specialty care among
children with public insurance versus those with private
insurance, mainly attributed to specialists’ reluctance to
accept public health insurance owing to decreased reimburse-
ments.7 Speciﬁcally, 66% (179) of callers reportingMedicaid–
Children’s Health Insurance Program coverage were denied
an appointment for specialty care when compared with 11%urnal of Preventive Medicine. Published by Elsevier Inc. This is an
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The Chronic Care Model is an evidence-based methodology
for providing comprehensive chronic disease management
and has been recommended as an effective strategy for
managing individuals with multiple comorbid conditions.8
The components of the Chronic Care Model include
community resources, health system organization, delivery
system design, clinical information systems, self-manage-
ment, and decision support. Application of the Chronic Care
Model during a prospective, observational study among
adults with SCD demonstrated improved adherence to care
processes associated with improved health outcomes.9 Sev-
eral studies have also demonstrated improved asthma-related
outcomes, speciﬁcally improved guideline and medication
adherence, symptom control, and quality of life, with
employment of the Chronic Care Model.10–13 Given the
evidence of improved outcomes with utilization of the
Chronic Care Model, an integrated SCD and asthma care
model was implemented to assess for improved adherence to
evidence-based guidelines and outcomes when compared
with a traditional model of SCD and asthma managed
separately by pulmonary and hematology specialists.
Methods
This quality improvement initiative was conducted using a pro-
spective, observational, pre–post study design. An integrated SCD
and asthma care model guided by the Care Model (an expanded
version of the Chronic Care Model) was created to improve asthma
control and SCD morbidity in children with SCD and asthma.
During the pre-intervention phase, participants were managed
separately by pulmonologists and hematologists in a tertiary
academic medical center. Participants were managed in an integrated
SCD and asthma clinic during the intervention phase. This study was
approved by the Vanderbilt University Medical Center IRB.
Setting
During the pre-intervention phase, 2010–2012, the care delivery model
for SCD and asthma was composed of separate hematology and
pulmonology specialty teams at a tertiary academic medical center. In
the intervention years, 2013–2014, co-management of SCD and asthma
was provided at a community-based federally qualiﬁed health center in
Nashville, TN, which offered extended evening and weekend hours.
The integration of comprehensive asthma management included1.Jula dual respiratory therapist and asthma case manager;
2. an SCD nurse practitioner with asthma educator certiﬁcation;
3. an onsite pulmonary function test laboratory;
4. a pediatrician with expertise in managing SCD and asthma; and
5. application of the National Asthma Education Prevention
Program’s Expert Panel Report 3 (NAEPP) guidelines.
During the 2012 transition phase from isolated specialty clinics
to the integrative model, the pediatric hematologist began seeing
patients in January 2012 and the nurse practitioner in Septembery 20162012. Prior to providing medical care for children with SCD, the
nurse practitioner trained 8 hours per week for 6 months with the
pediatric pulmonary and asthma team.
Asthma Management
Asthma management was delivered by a multidisciplinary team
following the NAEPP guidelines in accordance with the Care
Model (Figure 1). The multidisciplinary team was composed of a
pediatric hematologist, pediatric nurse practitioner, certiﬁed
respiratory therapist, and nurse case manager. The electronic
medical record (EMR) allowed for computerized documentation,
electronic prescribing, communication with primary care pro-
viders, and communication with patients and families through an
electronic patient portal (clinical information systems). The
NAEPP guidelines include standardized assessment and educa-
tional tools and were embedded in the electronic medical record,
providing a standardized, evidence-based structure for care
delivery (decision support). The certiﬁed respiratory therapist
reviewed asthma pathogenesis, environmental trigger recognition
and avoidance, treatment regimens, and medication delivery
techniques with each participant (self-management support).
Asthma exacerbations are typically managed with bronchodilators
and a 3- to 5-day course/burst of systemic corticorticoids.14 However,
multiple reports in the literature15,16 have demonstrated a temporal
risk of rebound vaso-occlusive pain in individuals with SCD who
receive even a single dose of steroids, leaving some hematologists
reluctant to prescribe steroids during asthma exacerbations. A one-
time 2-mg/kg/day dose (max 60 mg/dose) of systemic glucocorticoids
was used to treat asthma exacerbations during the intervention phase,
with a 24-hour follow-up and one repeat dose of 1 mg/kg/day if
needed, as the risk of untreated asthma exacerbations and resultant
hypoxia outweigh the potential threat of rebound pain.
Measures
Primary outcomes related to SCDmorbidity included vaso-occlusive
pain and ACS. Asthma outcome measures were selected based on
expert recommendations from the Asthma Outcomes Workshop, a
committee of experts convened by the National Institutes of Health
and Agency for Healthcare Research and Quality, and included
spirometry, asthma action plan utilization, lower airway obstruction,
and rates of asthma exacerbations.17 Outcome measures were
reviewed by two co-authors (BM and ZI). Study participant inclusion
criteria were as follows: a conﬁrmed diagnosis of SCD based on
hemoglobin analysis; consistent follow-up by the SCD team from
2010 to 2014; and a diagnosis of asthma, deﬁned as episodic
symptoms of airﬂow obstruction (exercise intolerance or nighttime
awakenings due to coughing or respiratory symptoms), reversible
airﬂow obstruction, and exclusion of alternative diagnoses.
Lower airway obstruction increases the risk of ACS in children
with SCD and is a clinical marker for asthma.3 Spirometry is the
gold standard for detecting lower airway obstruction and is
recommended annually for individuals with asthma.18,19 Spirome-
try was performed according to American Thoracic Society guide-
lines for all participants aged ≥5 years.20 The 2012 Global Lung
Initiative multi-ethnic prediction equations were used as reference
values.21 Spirometry was performed using the Morgan Plethysmo-
graph Body Box and ComPAS PFT software. Test procedure and
acceptability criteria were instituted according to American
Figure 1. Working care model for integrated sickle cell disease and asthma care in a community health system.
Note: Adapted from Improving Chronic Illness. http://improvingchroniccare.org/index.php?p=The_Chronic_Care_Model&s=2.
EMR, electronic medical record; PCP, primary care provider; SCD, sickle cell disease.
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that were measured include forced vital capacity (FVC); forced
expiratory volume in 1 second (FEV1); and the ratio of FEV1 to
FVC (FEV1/FVC). Lower airway obstruction was deﬁned as FEV1/
FVC less than the ﬁfth percentile after adjusting for age, gender,
height, and race.22 Results were reviewed for quality and inter-
preted by pediatric pulmonary function test laboratory personnel.
Asthma self-management is fostered through patient education
and written asthma action plans, which have been shown to reduce
emergent health service utilization.23 Study participants received
annual written asthma action plans, as well as updated treatment
plans based on steps up or down in therapy.
Vaso-occlusive pain episodes were deﬁned as hospitalizations
requiring intravenous opioid administration. The total number of
hospitalizations related to pain was determined through EMR
extraction for discharge diagnoses indicating SCD and vaso-
occlusive pain and ICD-9 codes coinciding with SCD and pain.
ACS was deﬁned as a new radiodensity on chest radiograph,
accompanied by fever, increased respiratory effort, or decreased oxygen
saturation.24,25 A diagnosis of pneumonia was considered an ACS
episode. Hospitalizations related to ACS were determined through
EMR extraction for chest radiograph ﬁndings indicating a new
radiodensity, documented discharge diagnoses for SCD and ACS or
pneumonia, and an ICD-9 code for ACS (517.3). Vaso-occlusive pain
and ACS occurring during the same admission were counted as ACS.
Asthma exacerbations were deﬁned as acute respiratory events
resulting in worsening shortness of breath, cough, wheezing, chest
tightness, or some combination of these symptoms.14 ED and
hospitalizations due to asthma exacerbations were captured
through EMR extraction. ICD-9 codes for asthma (493.9); plus
cough (786.2); wheezing (786.07); dyspnea (786.0); chest pain(786.5); or acute exacerbation (493.82) were counted as an asthma
exacerbation. Participants hospitalized for ACS with asthma
symptoms were classiﬁed as ACS and acute asthma exacerbation.
Statistical Analysis
Participant demographics were examined using descriptive sta-
tistics. Pre and post utilization of spirometry, asthma actions plans,
lung function, and systemic corticosteroid use were assessed using
a one-tailed Fisher’s exact test. ED and hospital encounters related
to asthma symptoms were compared using a two-rate person-time
comparison. Rates of vaso-occlusive pain and ACS were compared
using a Wilcoxon signed-rank test.
Results
The SCD practice team manages a total of 296 children
with SCD, of which 31% (93/296) have a comorbid
diagnosis of asthma. Of the 93 children with SCD and
asthma, 61 were managed by the SCD team all 5 study
years from 2010 to 2014 and were included in this study.
Of the 61 participants, 73% had hemoglobin (Hb) SS and
55.7% were male. The mean age at study entry was 6.8
years. Of the 42 participants with Hb SS or Hb Sβ0
thalassemia, who were not on chronic blood transfusion
therapy for primary or secondary stroke prevention, 98%
(41/42) were on hydroxyurea therapy. Asthma severity
was poorly documented during the pre-intervention
phase, inhibiting a before and after comparison ofwww.ajpmonline.org
Figure 2. American Thoracic Society/European Respiratory Society spirometry acceptability criteria.
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the intervention phase were as follows: 19.6% intermit-
tent, 27.8%mild persistent, 46%moderate persistent, and
6.5% severe persistent.
Among the 61 participants included in this study, 41
were aged ≥5 years during the study period and eligible
to undergo spirometry. Spirometry was performed at
either the tertiary academic medical center or commun-
ity-based SCD clinic. During the pre-intervention phase,
65% (27/41) of participants received spirometry. Spiro-
metry use increased to 95% (39/41) during the post-
intervention phase (po0.001).
Lower airway obstruction improved following the
implementation of the integrated SCD and asthma clinic.
During the pre-intervention phase, ten children with
SCD had evidence of lower airway obstruction, of which
30% (3/10) had improved lower airway obstruction to
above the ﬁfth percentile with application of the separate
specialty model. During the intervention phase, ten new
cases of lower airway obstruction were identiﬁed, of
which 80% (8/10) had a correction of lower airway
obstruction to above the ﬁfth percentile (p¼0.03) with
application of the NAEPP guidelines in the integrated
SCD and asthma model.
Asthma action plan utilization increased after imple-
mentation of comprehensive asthma management in theJuly 2016community-based SCD clinic. During the pre-interven-
tion phase, 45 participants had an established diagnosis
of asthma, and 16 participants were newly diagnosed
with asthma during the pre-intervention period. Of the
16 new diagnoses, nine (56%) received a written asthma
action plan at the time of diagnosis. There were 16 new
asthma diagnoses during the 2013–2014 intervention
phase. After combining comprehensive asthma manage-
ment with the community-based SCD clinic, 100% (16/
16) of participants newly diagnosed with asthma received
an asthma action plan at the time of diagnosis (p¼0.003).
Hospital and ED encounters related to asthma exacer-
bation decreased with the integrative model, but did not
reach statistical signiﬁcance. ED and hospital encounters
related to asthma symptoms before and after the integrative
model occurred at a rate of 9.29 events and 6.56 events per
100 patient-years, respectively (p¼0.38).
Rates of vaso-occlusive events (pain or ACS) did not
decrease after implementation of comprehensive asthma
management in the SCD clinic (Table 1). Hospital
admissions related to vaso-occlusive pain were
54.6 per 100 patient-years during the pre-intervention
phase and 48.9 per 100 patient-years during the
post-invention period (p¼0.54) among participants
with Hb SS and Hb Sβ0 thalassemia. Incidence
rates of ACS remained the same in the pre- and
McClain et al / Am J Prev Med 2016;51(1S1):S62–S68S66post-intervention phases. Hospital discharges for ACS
among participants with Hb SS and Hb Sβ0 thalassemia
were 21.3 and 26.6 per 100 patient-years before and after
implementation of asthma care in the SCD clinic,
respectively (p¼0.26).
The use of systemic corticosteroids for asthma exac-
erbations did not change statistically before and after the
integrative model. The intervention group (n¼11)
received fewer systemic corticosteroid bursts compared
to the pre-intervention group (n¼18); however, this
decrease in systemic corticosteroid use did not reach
statistical signiﬁcance (p¼0.10).
Discussion
Multiple studies have underlined the associated risk of
increased SCD-related morbidity in children with SCD and
concomitant asthma.3,5 However, no strategy has been
introduced to co-manage these two conditions. Given theTable 1. Overall Comparison of Standard Care Model Versus In
Number and location of initiation of asthma action plans for new diag
Asthma clinic (n¼16)
Sickle cell clinic (n¼16)
Spirometry utilization
Participants ≥5 years of age (n¼41)
Correction of lower airway obstruction after therapy
FEV1/FVC o5th percentile (n¼10 for both groups)
Asthma exacerbations
Emergency department and hospital encounters per 100 patient-ye
Systemic corticosteroids administered
Hospitalizations for vaso-occlusive pain per 100 patient-years
Entire cohort
Hemoglobin SS and sickle beta thalassemia null
Hemoglobin SC and sickle beta thalassemia þ
Hospitalizations for acute chest syndrome per 100 patient-years
Entire cohort
Hemoglobin SS and sickle beta thalassemia null
Hemoglobin SC and sickle beta thalassemia þ
Note: Boldface indicates statistical signiﬁcance (*po0.05; **po0.01).
FEV1/FVC, the ratio of forced expiratory volume in 1 second to forced vital cwell-established barriers to specialty care access among
children with public insurance,7 coupled with the fact that
approximately 60% of children with SCD have public
insurance,26 an integrative model is a promising strategy
for improving access to asthma specialty care for children
with SCD. The integrated SCD and asthma care model
provided access to both SCD and asthma expertise in a single
setting and led to improved adherence to evidence-based
asthma guidelines, a critical ﬁrst step for improved quality of
care. As a result of improved adherence to asthma care
guidelines, there was a statistically signiﬁcant decrease in
lower airway obstruction, a potential contributor to SCD-
related morbidity.27
Only one other study has examined the impact of the
Chronic Care Model in individuals with SCD. During this
10-year observational study of adults with SCD, adherence to
evidence-based guidelines, hydroxyurea use, health service
utilization, and hospital length of stay improved with
the incorporation of standardized disease managementtegrative Model
Standard asthma care
model: asthma specialty
clinic separate from sickle
cell clinic (2010–2012)
Integrated sickle
cell and asthma
clinic (2013–2014)
noses
4 (44%) 0
5 (56%) 16 (100%)*
27 (65%) 39 (95%)**
3 (30%) 8 (80%)*
ars 9.29 6.56
18 11
51 62
54.6 48.9
28.6 92.9*
24 20
21.3 26.6
26.2 17.9
apacity.
www.ajpmonline.org
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ment, and self-management support.9 This study was differ-
ent from the prior adult study in that the follow-up period
was signiﬁcantly shorter and was limited to children with
both SCD and asthma that were followed all 5 study years.
Despite these differences in implementation of the Chronic
Care Model, both studies highlight the potential merits of
applying the Chronic Care Model across the life span in
individuals with SCD.
The integrated SCD and asthma care model did not
improve incidence rates of vaso-occlusive pain, ACS, or
asthma exacerbations requiring ED or hospitalization
(Table 1). Given that the NAEPP guidelines have not been
tested in children with SCD, it is unknown whether the
current recommendations regarding preventive treatment or
an increase in asthma preventive therapy beyond what is
typically recommended in the general population is beneﬁcial
for children with SCD. Despite not having SCD-speciﬁc
guidelines, asthma is a well-established contributor to
increased SCD-related morbidity and should be detected
early and managed appropriately,18 further highlighting the
need for prospective clinical trials examining asthma thera-
pies in children with SCD and a concomitant diagnosis of
asthma.
Limitations
This study has several limitations. Ideally, children with SCD
and asthma would have been randomly allocated to receive
either standard care or the integrative care model; however,
this was a before and after observational study and random
allocation of participants was not feasible. Another limitation
in detecting the impact of the integrative model is the
relatively low baseline rates of vaso-occlusive pain and ACS
in the study cohort when compared with other cohorts (0.54
and 1.0225 per 100 patient-years),28 most likely due to the
high use of hydroxyurea therapy (98%) and inability to adjust
for this potential confounder. Despite these ﬁndings, an
integrative model improves guideline adherence, a critical
determinant of treatment effectiveness.Replication of an Integrative Care Model. The inte-
grated clinic was funded in part by the Junior League of
Nashville Medical Home Program and Health Resources
Service Administration to establish a medical home for
children and adults with SCD. The funding for this novel
model of care facilitated its initiation and propagation.
However, based on prior and current experiences of
delivering asthma care in an SCD clinic, the integrated
care model can be implemented without extra funding.
The effort requires cross-training, wherein mid-level and
subspecialty providers are trained to manage both SCD
and asthma. Further, adding extended evening and
weekend hours is critical to this integrative model, asJuly 2016these hours of availability eliminate the barrier of missed
days from school and work for many single-headed
household families.
Conclusions
Comprehensive asthma management in children with
SCD addresses a signiﬁcant contributor to SCD-related
morbidity. Innovative strategies to increase access to
SCD and asthma care improve adherence to evidence-
based guidelines. The Chronic Care Model provides a
comprehensive framework for dual disease management
of individuals with multiple comorbidities, including
children with SCD and asthma. Larger multicenter
studies are needed to determine the impact, if any, of
integrated SCD and asthma management according to
the NAEPP guidelines on rates on vaso-occlusive pain
and ACS in children with SCD.
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